drugset / Trial / NCT03925675

18F-Fluciclovine PET and Multiparametric MR Imaging

NCT03925675

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study is to investigate the use of the investigational agent Axumin (fluciclovine-F18) with PET/CT imaging in combination with standard MR imaging to detect remaining or recurrent brain tumor.

Timeline

Start
2020-08-24
Primary completion
2023-08-31
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluciclovine Diagnostic / imaging agent

Indications